Sphingosine 1‐phosphate is a ligand for peroxisome proliferator‐activated receptor‐γ that regulates neoangiogenesis

Sphingosine 1‐phosphate (S1P) is a bio‐active lipid that can function both extracellularly and intracellularly to mediate a variety of cellular processes. Using lipid affinity matrices and a radiolabeled lipid binding assay, we reveal that S1P directly interacts with the transcription factor peroxisome proliferator‐activated receptor (PPAR) γ. Herein, we show that S1P treatment of human endothelial cells (ECs) activated a luciferase‐tagged PPAR‐γ‐specific gene reporter by ~12‐fold, independent of the S1P receptors. More specifically, in silico docking, gene reporter, and binding assays revealed that His323 of the PPAR‐γ ligand binding domain is important for binding to S1P. PPAR‐γ functions when associated with coregulatory proteins, and herein we identify that peroxisome proliferator‐activated receptor‐γ coactivator 1 (PGC1)β binds to PPAR‐γ in ECs and their progenitors (nonadherent endothelial forming cells) and that the formation of this PPAR‐γ:PGC1β complex is increased in response to S1P. ECs treated with S1P selectively regulated known PPAR‐γ target genes with PGC1β and plasminogen‐activated inhibitor‐1 being increased, no change to adipocyte fatty acid binding protein 2 and suppression of CD36. S1P‐induced in vitro tube formation was significantly attenuated in the presence of the PPAR‐γ antagonist GW9662, and in vivo application of GW9662 also reduced vascular development in Matrigel plugs. Interestingly, activation of PPAR‐γ by the synthetic ligand troglitazone also reduced tube formation in vitro and in vivo. To support this, Sphk1‐/‐ Sphk2+/‐ mice, with low circulating S1P levels, demonstrated a similar reduction in vascular development. Taken together, our data reveal that the transcription factor, PPAR‐γ, is a bona fide intracellular target for S1P and thus suggest that the SlP:PPAR‐γ:PGC1β complex may be a useful target to manipulate neovascularization.—Parham, K. A., Zebol, J. R., Tooley, K. L., Sun, W. Y., Moldenhauer, L. M., Cockshell, M. P., Gliddon, B. L., Moretti, P. A., Tigyi, G., Pitson, S. M., Bonder, C. S. Sphingosine 1‐phosphate is a ligand for peroxisome proliferator‐activated receptor‐γ that regulates neoangiogenesis. FASEB J. 29, 3638‐3653 (2015). www.fasebj.org

[1]  Cheng Luo,et al.  K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5 , 2014, Nature Immunology.

[2]  S. Erzurum,et al.  Fatty acid binding protein 4 regulates VEGF-induced airway angiogenesis and inflammation in a transgenic mouse model: implications for asthma. , 2013, The American journal of pathology.

[3]  Jiandie D. Lin,et al.  Peroxisome Proliferator-activated Receptor γ Coactivator 1β (PGC-1β) Protein Attenuates Vascular Lesion Formation by Inhibition of Chromatin Loading of Minichromosome Maintenance Complex in Smooth Muscle Cells* , 2012, The Journal of Biological Chemistry.

[4]  P. Dentelli,et al.  Increase of Palmitic Acid Concentration Impairs Endothelial Progenitor Cell and Bone Marrow–Derived Progenitor Cell Bioavailability , 2012, Diabetes.

[5]  Angel F. Lopez,et al.  Characterization of a Distinct Population of Circulating Human Non-Adherent Endothelial Forming Cells and Their Recruitment via Intercellular Adhesion Molecule-3 , 2012, PloS one.

[6]  S. Corvera,et al.  Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial , 2012, Diabetologia.

[7]  V. Christiaens,et al.  CD36 promotes adipocyte differentiation and adipogenesis. , 2012, Biochimica et biophysica acta.

[8]  J. Pfeilschifter,et al.  Thiazolidinedione‐dependent activation of sphingosine kinase 1 causes an anti‐fibrotic effect in renal mesangial cells , 2012, British journal of pharmacology.

[9]  A. Nurul,et al.  The Modulation of PPARγ1 and PPARγ2 mRNA Expression by Ciglitazone in CD3/CD28-Activated Naïve and Memory CD4+ T Cells , 2012, Clinical & developmental immunology.

[10]  M. Hickey,et al.  Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. , 2012, The American journal of pathology.

[11]  Eugene Y. Kim,et al.  Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. , 2012, Cancer research.

[12]  S. Pitson,et al.  Over‐Expression of Sphingosine Kinase‐1 Enhances a Progenitor Phenotype in Human Endothelial Cells , 2011, Microcirculation.

[13]  T. Itakura,et al.  Cilostazol Activates Function of Bone Marrow-Derived Endothelial Progenitor Cell for Re-endothelialization in a Carotid Balloon Injury Model , 2011, PloS one.

[14]  Cholsoon Jang,et al.  PGC-1β regulates angiogenesis in skeletal muscle. , 2011, American journal of physiology. Endocrinology and metabolism.

[15]  Jiandie D. Lin,et al.  PGC-1 coactivators in the control of energy metabolism. , 2011, Acta biochimica et biophysica Sinica.

[16]  S. Pitson Regulation of sphingosine kinase and sphingolipid signaling. , 2011, Trends in biochemical sciences.

[17]  D. C. Simpson,et al.  Sphingosine‐1‐phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  S. Pitson,et al.  Tumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial {alpha}5{beta}1 integrin. , 2010, The American journal of pathology.

[19]  Cheng Luo,et al.  SPHINGOSINE-1-PHOSPHATE: A MISSING COFACTOR FOR THE E3 UBIQUITIN LIGASE TRAF2 , 2010, Nature.

[20]  C. Glass,et al.  Pharmacological correction of a defect in PPARγ signaling ameliorates disease severity in Cftr-deficient mice , 2010, Nature Medicine.

[21]  R. Proia,et al.  Sphingosine 1-Phosphate Lyase Deficiency Disrupts Lipid Homeostasis in Liver* , 2010, The Journal of Biological Chemistry.

[22]  J. Gamble,et al.  Sphingosine kinase-1 associates with integrin {alpha}V{beta}3 to mediate endothelial cell survival. , 2009, The American journal of pathology.

[23]  Cheng Luo,et al.  Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate , 2009, Science.

[24]  F. Goñi,et al.  Sphingosine-1-phosphate as an amphipathic metabolite: its properties in aqueous and membrane environments. , 2009, Biophysical journal.

[25]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[26]  J. Gamble,et al.  Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation. , 2009, Blood.

[27]  Y. Hannun,et al.  Role for sphingosine kinase 1 in colon carcinogenesis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  F. Orso,et al.  Formation of STAT5/PPARγ Transcriptional Complex Modulates Angiogenic Cell Bioavailability in Diabetes , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Hsinyu Lee,et al.  Prostaglandins and Other Lipid Mediators ysophosphatidic acid-induced oxidized low-density lipoprotein ptake is class A scavenger receptor-dependent in macrophages , 2008 .

[30]  T. Karn,et al.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer , 2008, Breast Cancer Research and Treatment.

[31]  T. Hla,et al.  The vascular S1P gradient-cellular sources and biological significance. , 2008, Biochimica et biophysica acta.

[32]  Barbara S. Paugh,et al.  Sphingosine-1-Phosphate and Interleukin-1 Independently Regulate Plasminogen Activator Inhibitor-1 and Urokinase-Type Plasminogen Activator Receptor Expression in Glioblastoma Cells: Implications for Invasiveness , 2008, Molecular Cancer Research.

[33]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[34]  V. Limaye The role of sphingosine kinase and sphingosine-1-phosphate in the regulation of endothelial cell biology. , 2008, Endothelium : journal of endothelial cell research.

[35]  G. Yan,et al.  Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. , 2008, Cardiovascular research.

[36]  N. Sugimoto,et al.  The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice. , 2008, Cardiovascular research.

[37]  J. Pfeilschifter,et al.  Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. , 2008, Biochemical and biophysical research communications.

[38]  Chulhee Choi,et al.  Peroxisome proliferator activated receptor gamma agonists suppress TNFalpha-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species. , 2008, Immunology letters.

[39]  M. Vadas,et al.  Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity* , 2008, Journal of Biological Chemistry.

[40]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[41]  A. Margeli,et al.  Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis , 2007, Expert opinion on investigational drugs.

[42]  U. Laufs,et al.  The Peroxisome Proliferator–Activated Receptor-γ Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance , 2007, Diabetes.

[43]  Chiung-Nien Chen,et al.  Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3. , 2007, Biochemical and biophysical research communications.

[44]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[45]  W. Garvey,et al.  Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. , 2006, Atherosclerosis.

[46]  Satoshi Yasuda,et al.  Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.

[47]  R. Proia,et al.  Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.

[48]  J. Passauer,et al.  PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells , 2005 .

[49]  Korey R. Johnson,et al.  Immunohistochemical Distribution of Sphingosine Kinase 1 in Normal and Tumor Lung Tissue , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  Thomas W Prior,et al.  Sphingosine Kinase-1 Expression Correlates With Poor Survival of Patients With Glioblastoma Multiforme: Roles of Sphingosine Kinase Isoforms in Growth of Glioblastoma Cell Lines , 2005, Journal of neuropathology and experimental neurology.

[51]  Matej Oresic,et al.  The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. , 2005, Diabetes.

[52]  J. Gamble,et al.  Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. , 2005, Blood.

[53]  T. Wurch,et al.  Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands , 2004, Journal of Pharmacology and Experimental Therapeutics.

[54]  T. Hla Physiological and pathological actions of sphingosine 1-phosphate. , 2004, Seminars in cell & developmental biology.

[55]  M. Al-Omran,et al.  Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage: A New Paradigm in Glitazone Pleiotropy , 2004, Circulation.

[56]  I. Morita,et al.  Expression and function of PPARγ in rat placental development , 2004 .

[57]  M. Tötsch,et al.  Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). , 2004, Cancer letters.

[58]  J. C. Hinshaw,et al.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Vadas,et al.  The Nucleotide-binding Site of Human Sphingosine Kinase 1* , 2002, The Journal of Biological Chemistry.

[60]  T. Panetti Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells. , 2002, Biochimica et biophysica acta.

[61]  Y. Kawahito,et al.  Expression of peroxisome proliferator‐activated receptor (PPAR) in human prostate cancer , 2002, The Prostate.

[62]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[63]  J. Gamble,et al.  Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. , 2000, The Biochemical journal.

[64]  M. Fujishima,et al.  Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. , 2000, Biochimica et biophysica acta.

[65]  M. Lazar,et al.  A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.

[66]  Y. G. Kwon,et al.  Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. , 1999, Biochemical and biophysical research communications.

[67]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[68]  M. Gerritsen,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo * , 1999, The Journal of Biological Chemistry.

[69]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[70]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[71]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[72]  C. H. Liu,et al.  Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. , 1998, Science.

[73]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[74]  A. Daugherty,et al.  Scavenger receptors are present on rabbit aortic endothelial cells in vivo. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[75]  J. Gamble,et al.  Novel Cytokine-independent Induction of Endothelial Adhesion Molecules Regulated by Platelet/Endothelial Cell Adhesion Molecule (CD31) , 1997, The Journal of cell biology.

[76]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[77]  J. Flier,et al.  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. , 1997, The Journal of biological chemistry.

[78]  Y. Igarashi,et al.  Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. , 1997, Journal of biochemistry.

[79]  R. Hantgan,et al.  Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. , 1996, Blood.

[80]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[81]  T. Wick,et al.  Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. , 1992, Journal of immunology.

[82]  B. Zetter,et al.  Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein , 1984, The Journal of cell biology.

[83]  M. Brown,et al.  Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[85]  W. Daniel,et al.  Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-α. , 2011, Clinical hemorheology and microcirculation.

[86]  M. Maceyka,et al.  Extracellular and intracellular actions of sphingosine-1-phosphate. , 2010, Advances in experimental medicine and biology.

[87]  J. Passauer,et al.  PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. , 2005, Atherosclerosis.

[88]  I. Morita,et al.  Expression and function of PPARgamma in rat placental development. , 2004, Biochemical and biophysical research communications.

[89]  A. Margeli,et al.  Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) Ligands and Angiogenesis , 2004, Angiogenesis.

[90]  B. Spiegelman,et al.  PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. , 2001, The Journal of biological chemistry.

[91]  R. Evans,et al.  PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.

[92]  M. Lazar,et al.  A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. , 2000, The Journal of biological chemistry.

[93]  P. Libby,et al.  PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[94]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.